- +91 8471002000
- Messenger
Immunotherapy
Pembrolizumab
Pembrolizumab Injection
Injection
Brand name: Keytruda Manufacturer: Merck & Co., Inc.
Pembrolizumab Dose: 200mg via IV infusion every 3 weeks
Pembrolizumab, a remarkable drug, has gained approval for treating various cancers, such as melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin's lymphoma, urothelial carcinoma, and gastric and esophageal cancers. Moreover, it demonstrates effectiveness against tumors with microsatellite instability or impaired mismatch repair. This innovative medication strengthens the body's immune system, empowering it to effectively combat and eliminate cancerous growths.
Pembrolizumab embodies a groundbreaking immunotherapy technique, bolstering patients' immune defenses to identify and eliminate malignant cells. Cleverly obstructing PD-1 protein functions, it counteracts cancer's immune evasion, thereby enhancing immune fortitude. This ingenious approach showcases pembrolizumab's remarkable adaptability against various cancers, ushering in a new age of tailored cancer treatment paradigms.
Resistance to pembrolizumab occurs due to alterations in the tumor's cellular makeup, hindering immune checkpoint blockade and limiting T-cell engagement. Consequently, cancer antigen exposure declines and suppressive components escalate, ultimately compromising pembrolizumab's effectiveness and diminishing its ability to efficiently combat cancer progression.
The administration of Pembrolizumab injection can lead to several unintended outcomes, including persistent weariness, continuous cough, feelings of nausea, and exacerbated dermatological issues. In certain cases, this treatment may trigger serious events such as attacks on one's own organs, pulmonary inflammation, liver concerns, or intense injection-related troubles. Continuous monitoring is crucial for early identification and handling of these potential hazards.
Pembrolizumab, a powerful anti-cancer treatment, can be combined with different medications based on the cancer type. In non-squamous NSCLC cases, it is frequently combined with pemetrexed and platinum-based chemotherapy drugs like cisplatin or carboplatin. Additionally, the FDA has approved the simultaneous use of pembrolizumab and axitinib for tackling advanced RCC. Consultation with a healthcare professional is crucial to devise an appropriate treatment strategy.
Typical Pembrolizumab Injection price: ₹63,000 in India. The above price is specific for Dhrangadhra, Gujarat, India
WhatsApp us